CY1115946T1 - Ορθο-συμπυκνωμενα παραγωγα πυριδινης και πυριμιδινης (π.χ. πουρινες) ως αναστολεις πρωτεϊνικων κινασων - Google Patents
Ορθο-συμπυκνωμενα παραγωγα πυριδινης και πυριμιδινης (π.χ. πουρινες) ως αναστολεις πρωτεϊνικων κινασωνInfo
- Publication number
- CY1115946T1 CY1115946T1 CY20141100991T CY141100991T CY1115946T1 CY 1115946 T1 CY1115946 T1 CY 1115946T1 CY 20141100991 T CY20141100991 T CY 20141100991T CY 141100991 T CY141100991 T CY 141100991T CY 1115946 T1 CY1115946 T1 CY 1115946T1
- Authority
- CY
- Cyprus
- Prior art keywords
- group
- carbon atoms
- hydrogen
- linker
- optionally
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000003212 purines Chemical class 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 7
- 125000005647 linker group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229930195733 hydrocarbon Natural products 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 108091008611 Protein Kinase B Proteins 0.000 abstract 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62182104P | 2004-10-25 | 2004-10-25 | |
| GB0423655A GB0423655D0 (en) | 2004-10-25 | 2004-10-25 | Pharmaceutical compounds |
| US68411905P | 2005-05-24 | 2005-05-24 | |
| EP10184485.0A EP2272517B2 (en) | 2004-10-25 | 2005-10-25 | Ortho -condensed pyridine and pyrimidine derivatives (e.g. purines) as protein kinases inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115946T1 true CY1115946T1 (el) | 2017-01-25 |
Family
ID=35715573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100991T CY1115946T1 (el) | 2004-10-25 | 2014-11-27 | Ορθο-συμπυκνωμενα παραγωγα πυριδινης και πυριμιδινης (π.χ. πουρινες) ως αναστολεις πρωτεϊνικων κινασων |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8546407B2 (https=) |
| EP (2) | EP2272517B2 (https=) |
| JP (1) | JP5128284B2 (https=) |
| AR (1) | AR051342A1 (https=) |
| AT (1) | ATE513549T1 (https=) |
| CY (1) | CY1115946T1 (https=) |
| DK (1) | DK2272517T4 (https=) |
| ES (1) | ES2523266T5 (https=) |
| MY (1) | MY179032A (https=) |
| PL (1) | PL2272517T5 (https=) |
| PT (1) | PT2272517E (https=) |
| SI (1) | SI2272517T2 (https=) |
| UY (1) | UY29176A1 (https=) |
| WO (1) | WO2006046024A1 (https=) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| EP2354140A1 (en) * | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| WO2007007919A2 (en) | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| DE102005037733A1 (de) * | 2005-08-10 | 2007-02-15 | Merck Patent Gmbh | Adeninderivate |
| CA2621261C (en) | 2005-09-22 | 2014-05-20 | Incyte Corporation | Azepine inhibitors of janus kinases |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| WO2007084667A2 (en) * | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| DK3421471T3 (da) * | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
| JP2009534456A (ja) * | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| EP2037931A2 (en) * | 2006-04-25 | 2009-03-25 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| WO2008012635A2 (en) * | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| PL2069352T3 (pl) * | 2006-08-02 | 2014-03-31 | Cytokinetics Inc | Określone cząstki chemiczne, kompozycje i sposoby |
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| CA2660114A1 (en) * | 2006-08-09 | 2008-02-14 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| AR064415A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
| AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| CA2673038C (en) | 2006-12-22 | 2015-12-15 | Incyte Corporation | Substituted tricyclic heteroaryl compounds as janus kinase inhibitors |
| EP2139478A4 (en) * | 2007-03-30 | 2010-05-05 | Cytokinetics Inc | CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| EP2141994A4 (en) * | 2007-04-26 | 2011-05-18 | Avalon Pharmaceuticals | POLYCYCLIC COMPOUNDS AND USES THEREOF |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| EP2209786B1 (en) * | 2007-10-05 | 2013-02-27 | Verastem, Inc. | Pyrimidine substituted purine derivatives |
| PL2201012T3 (pl) * | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| AU2009239500B2 (en) | 2008-04-21 | 2014-01-30 | Lexicon Pharmaceuticals, Inc. | LIMK2 inhibitors, compositions comprising them, and methods of their use |
| EP2355821A1 (en) | 2008-11-11 | 2011-08-17 | Eli Lilly and Company | P70 s6 kinase inhibitor and egfr inhibitor combination therapy |
| AR074072A1 (es) | 2008-11-11 | 2010-12-22 | Lilly Co Eli | Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme |
| SI2432472T1 (sl) | 2009-05-22 | 2019-11-29 | Incyte Holdings Corp | 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EA021478B1 (ru) | 2009-10-09 | 2015-06-30 | Инсайт Корпорейшн | ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| EA020151B1 (ru) | 2009-10-23 | 2014-09-30 | Эли Лилли Энд Компани | Ингибиторы akt и фармацевтические составы, их содержащие |
| NZ599830A (en) | 2009-11-05 | 2014-08-29 | Rhizen Pharmaceuticals Sa | Novel kinase modulators |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| EP2616464B1 (en) * | 2010-09-17 | 2018-01-03 | Mallinckrodt LLC | Improved process for the preparation of a precursor of sufentanil base |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| ES2617339T3 (es) | 2010-12-16 | 2017-06-16 | Calchan Limited | Derivados de pirrolopirimidina inhibidores de ASK1 |
| ES2547916T3 (es) | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
| EA027506B1 (ru) | 2011-04-01 | 2017-08-31 | Астразенека Аб | Способ лечения рака молочной железы |
| PH12013502240B1 (en) | 2011-05-04 | 2018-06-27 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of protein kinase |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| BR112014000742A2 (pt) | 2011-07-13 | 2016-08-23 | Andrew A Wolff | terapia de combinação de als |
| EP2741747A1 (en) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | JAK P13K/mTOR COMBINATION THERAPY |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| HRP20191982T4 (hr) | 2011-11-30 | 2023-01-06 | Astrazeneca Ab | Kombinacijsko liječenje raka |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| RS56494B1 (sr) | 2012-07-04 | 2018-01-31 | Rhizen Pharmaceuticals S A | Selektivni inhibitori pi3k delta |
| PH12020551186B1 (en) | 2012-11-15 | 2024-03-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| SMT202000315T1 (it) | 2013-08-07 | 2020-07-08 | Incyte Corp | Forme di dosaggio a rilascio prolungato per un inibitore di jak1 |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| EP3316877B1 (en) | 2015-07-02 | 2019-10-30 | Horizon Orphan LLC | Ado-resistant cysteamine analogs and uses thereof |
| TW201726140A (zh) | 2015-09-17 | 2017-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之新型生物標記及方法 |
| US11238334B2 (en) | 2017-04-04 | 2022-02-01 | Hailo Technologies Ltd. | System and method of input alignment for efficient vector operations in an artificial neural network |
| US11551028B2 (en) | 2017-04-04 | 2023-01-10 | Hailo Technologies Ltd. | Structured weight based sparsity in an artificial neural network |
| US12430543B2 (en) | 2017-04-04 | 2025-09-30 | Hailo Technologies Ltd. | Structured sparsity guided training in an artificial neural network |
| US10387298B2 (en) | 2017-04-04 | 2019-08-20 | Hailo Technologies Ltd | Artificial neural network incorporating emphasis and focus techniques |
| US11544545B2 (en) | 2017-04-04 | 2023-01-03 | Hailo Technologies Ltd. | Structured activation based sparsity in an artificial neural network |
| US11615297B2 (en) | 2017-04-04 | 2023-03-28 | Hailo Technologies Ltd. | Structured weight based sparsity in an artificial neural network compiler |
| EP3697786B1 (en) | 2017-10-18 | 2022-08-31 | Blueprint Medicines Corporation | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| SG11202007164UA (en) | 2018-01-30 | 2020-08-28 | Incyte Corp | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| JP7717065B2 (ja) | 2019-11-22 | 2025-08-01 | インサイト コーポレーション | Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法 |
| CN115210229A (zh) | 2020-01-03 | 2022-10-18 | 博格有限责任公司 | 多环酰胺作为治疗癌症的ube2k调节剂 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL297170A (https=) | 1963-04-04 | 1900-01-01 | ||
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| IT1252567B (it) | 1991-12-20 | 1995-06-19 | Italfarmaco Spa | Derivati di 5-isochinolinsolfonammidi inibitori delle protein-chinasi |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| AU1441497A (en) * | 1996-01-23 | 1997-08-20 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
| EP0944388A4 (en) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| CN1264381A (zh) | 1997-08-05 | 2000-08-23 | 辉瑞产品公司 | 4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药 |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| JP4611524B2 (ja) | 1998-06-02 | 2011-01-12 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | ピロロ［２，３ｄ］ピリミジン組成物およびその使用 |
| AU4231299A (en) | 1998-06-04 | 1999-12-20 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| SK286640B6 (sk) | 1998-06-19 | 2009-03-05 | Pfizer Products Inc. | Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva |
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| CO5271715A1 (es) * | 1999-12-21 | 2003-04-30 | Sugen Inc | 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa |
| IL136458A0 (en) | 2000-05-30 | 2001-06-14 | Peptor Ltd | Protein kinase inhibitors |
| EP1315714B1 (en) | 2000-08-31 | 2005-11-09 | F. Hoffmann-La Roche Ag | Quinazoline derivatives as alpha-1 adrenergic antagonists |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| CA2430577A1 (en) | 2000-12-01 | 2002-07-25 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| DK1474425T3 (da) | 2002-01-07 | 2006-09-25 | Eisai Co Ltd | Deazapuriner og anvendelser deraf |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| JPWO2004002531A1 (ja) | 2002-06-26 | 2005-10-27 | 小野薬品工業株式会社 | 血管の収縮または拡張による疾患治療剤 |
| US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| WO2004043380A2 (en) | 2002-11-08 | 2004-05-27 | President And Fellows Of Harvard College | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors |
| CN100376573C (zh) | 2002-12-04 | 2008-03-26 | 卫材R&D管理有限公司 | 稠合的1,3-二氢-咪唑环化合物 |
| EP1444982A1 (de) * | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
| SE0300457D0 (sv) | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| CA2518398A1 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
| US20060128956A1 (en) | 2003-04-21 | 2006-06-15 | Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky | (Purin-6-yl) amino acid and production method thereof |
| FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1663204B1 (en) | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
| WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| NZ590160A (en) | 2003-11-21 | 2012-07-27 | Array Biopharma Inc | AKT protein kinase inhibitors |
| EP1698375B1 (en) | 2003-12-25 | 2014-04-02 | Ono Pharmaceutical Co., Ltd. | Azetidine ring compounds and drugs comprising the same |
| WO2005117909A2 (en) * | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| MY179032A (en) * | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| JP5274842B2 (ja) | 2004-12-28 | 2013-08-28 | エグゼリクシス， インコーポレイテッド | 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物 |
| FR2880540B1 (fr) | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
| FR2880626B1 (fr) | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
| WO2006091450A1 (en) | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
| US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| WO2007007919A2 (en) | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| DK3421471T3 (da) | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
| WO2007125315A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP2009534456A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| EP2037931A2 (en) | 2006-04-25 | 2009-03-25 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| JP2009534454A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
| PL2201012T3 (pl) | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
-
2005
- 2005-10-21 MY MYPI20054963A patent/MY179032A/en unknown
- 2005-10-24 UY UY29176A patent/UY29176A1/es not_active IP Right Cessation
- 2005-10-25 EP EP10184485.0A patent/EP2272517B2/en not_active Expired - Lifetime
- 2005-10-25 AT AT05797685T patent/ATE513549T1/de not_active IP Right Cessation
- 2005-10-25 PT PT101844850T patent/PT2272517E/pt unknown
- 2005-10-25 ES ES10184485.0T patent/ES2523266T5/es not_active Expired - Lifetime
- 2005-10-25 JP JP2007538500A patent/JP5128284B2/ja not_active Expired - Lifetime
- 2005-10-25 US US11/577,963 patent/US8546407B2/en active Active
- 2005-10-25 EP EP20050797685 patent/EP1812004B1/en not_active Expired - Lifetime
- 2005-10-25 WO PCT/GB2005/004119 patent/WO2006046024A1/en not_active Ceased
- 2005-10-25 SI SI200531910T patent/SI2272517T2/sl unknown
- 2005-10-25 PL PL10184485T patent/PL2272517T5/pl unknown
- 2005-10-25 DK DK10184485.0T patent/DK2272517T4/da active
- 2005-10-25 AR ARP050104467 patent/AR051342A1/es active IP Right Grant
-
2013
- 2013-09-04 US US14/017,814 patent/US8809336B2/en not_active Expired - Lifetime
-
2014
- 2014-06-20 US US14/310,475 patent/US9006430B2/en not_active Expired - Lifetime
- 2014-11-27 CY CY20141100991T patent/CY1115946T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2523266T5 (es) | 2017-12-29 |
| US9006430B2 (en) | 2015-04-14 |
| WO2006046024A1 (en) | 2006-05-04 |
| US20140107137A1 (en) | 2014-04-17 |
| PT2272517E (pt) | 2014-12-04 |
| EP2272517A1 (en) | 2011-01-12 |
| ES2523266T3 (es) | 2014-11-24 |
| PL2272517T3 (pl) | 2015-04-30 |
| US8546407B2 (en) | 2013-10-01 |
| US20140303177A1 (en) | 2014-10-09 |
| JP2008517984A (ja) | 2008-05-29 |
| ATE513549T1 (de) | 2011-07-15 |
| US8809336B2 (en) | 2014-08-19 |
| HK1110503A1 (en) | 2008-07-18 |
| MY179032A (en) | 2020-10-26 |
| AR051342A1 (es) | 2007-01-03 |
| US20090247538A1 (en) | 2009-10-01 |
| PL2272517T5 (pl) | 2018-04-30 |
| EP2272517B1 (en) | 2014-10-01 |
| UY29176A1 (es) | 2006-05-31 |
| SI2272517T1 (sl) | 2015-01-30 |
| JP5128284B2 (ja) | 2013-01-23 |
| SI2272517T2 (sl) | 2017-12-29 |
| DK2272517T3 (da) | 2014-10-27 |
| EP1812004A1 (en) | 2007-08-01 |
| EP2272517B2 (en) | 2017-09-20 |
| EP1812004B1 (en) | 2011-06-22 |
| DK2272517T4 (da) | 2017-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115946T1 (el) | Ορθο-συμπυκνωμενα παραγωγα πυριδινης και πυριμιδινης (π.χ. πουρινες) ως αναστολεις πρωτεϊνικων κινασων | |
| WO2007125321A3 (en) | Purine and deazapurine derivatives as pharmaceutical compounds | |
| WO2007125315A3 (en) | Pharmaceutical compounds | |
| CY1111493T1 (el) | Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης | |
| NO20066015L (no) | Fuserte heterosykliske forbindelser | |
| AR117916A1 (es) | Compuesto heterocíclico y su uso | |
| UY30830A1 (es) | Piperidinas sustituidas que presentan actividad inhibitoria de proteinquinasa | |
| CY1111069T1 (el) | Παραγωγα διυδροπυραζολοπυριμιδινονης | |
| CY1121599T1 (el) | Νεο παραγωγο αμινης ή αλας αυτου ως παρεμποδιστες tnf αλφα | |
| AR074596A1 (es) | Derivados de (3-oxo) piridazin-4-ilurea | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| ES2452299T3 (es) | Compuestos heterocíclicos fungicidas | |
| ECSP099335A (es) | Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos | |
| MX2007012659A (es) | Derivados de hidroxi-benzamida y su uso como inhibidores de hsp90. | |
| DE60309848D1 (de) | Purinderivate als kinaseinhibitoren | |
| CY1117544T1 (el) | Παραγωγο 6-ακυλο-1,2,4-τριαζινο-3,5-διονης και ζιζανιοκτονα | |
| AR081859A1 (es) | Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr | |
| CY1111706T1 (el) | Παραγωγα αρυλο- και ετεροαρυλο-πιπεριδινοκαρβοξυλικων αλατων, η παρασκευη τους και η εφαρμογη τους ως αναστολεις του ενζυμου faah | |
| AR066606A1 (es) | Compuestos de heteroarilamida pirimidona | |
| BRPI0606455A (pt) | compostos farmacêuticos | |
| CY1112006T1 (el) | Μακροκυκλικοι αναστολεις του ιου της ηπατιτιδας c | |
| UY31014A1 (es) | Derivados de ftalazinona | |
| CY1113812T1 (el) | Ετεροκυκλικη ενωση και φαρμακευτικη συνθεση αυτης | |
| CY1115536T1 (el) | Νεες υδροξυ-6-ετεροαρυλφαινανθριδινες και χρηση αυτων ως αναστολεις pde4 |